
Please try another search
Jan 28 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS PROVIDES ENROLLMENT UPDATE FOR ITS PHASE 3 PRESECO TRIAL EVALUATING THE ORAL ANTIVIRAL FAVIPIRAVIR AS AN EARLY TREATMENT IN COVID-19
* APPILI THERAPEUTICS INC - COMPANY IS PRIORITIZING RESOURCES ON PIVOTAL STUDY AND EXPECTS TO PROVIDE INTERIM DATA READOUT BY LATE MARCH 2021
* APPILI THERAPEUTICS - 12 SITES IN U.S. ACTIVELY RECRUITING FOR DOUBLE-BLIND PLACEBO-CONTROLLED STUDY IN MILD-TO-MODERATE PATIENTS WITH COVID-19
* APPILI THERAPEUTICS INC - PRESECO IS EVALUATING FAVIPIRAVIR, AN ORAL ANTIVIRAL, IN EARLY TREATMENT OF COVID-19 IN OUTPATIENT SETTING
* APPILI THERAPEUTICS INC - PURSUING REGULATORY APPROVALS TO EXPAND PRESECO INTO SITES IN MEXICO, BRAZIL, AND COLOMBIA
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.